FDA Approves Lipfendra, First Oral PCSK9 Cholesterol Pill

The US Food and Drug Administration has approved Lipfendra, making Merck’s enlicitide the first once-daily oral PCSK9 inhibitor cleared for adults who need additional help lowering LDL, commonly called “bad” cholesterol.

The prescription tablet offers the first oral alternative to injectable PCSK9 medicines for adults who need additional LDL cholesterol lowering despite diet and other cholesterol-lowering therapies.

Lipfendra is approved for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, or HeFH, an inherited condition that can cause unusually high cholesterol from an early age. It is intended for use alongside diet, exercise and other LDL-lowering treatments.

How much can Lipfendra lower LDL?

The FDA decision was supported by Phase 3 studies from Merck’s CORALreef clinical programme. In one trial, Lipfendra reduced LDL cholesterol by about 56% compared with placebo after 24 weeks among adults who still needed further lowering despite stable treatment.

A separate study involving adults with HeFH recorded an LDL reduction of approximately 59%, while another analysis placed the decline near 60%. Individual results may vary according to starting cholesterol levels, accompanying medicines and how consistently the tablet is taken.

After the CORALreef trials demonstrated substantial LDL reductions, Merck submitted Lipfendra for regulatory review. The FDA approved the medicine on 16 July 2026, making it the first oral PCSK9 inhibitor cleared for use.

How the first oral PCSK9 inhibitor works

PCSK9 is a protein that contributes to the breakdown of LDL receptors in the liver. These receptors help remove cholesterol from the bloodstream. Lipfendra blocks PCSK9, leaving more receptors available to clear LDL from the blood.

Injectable treatments such as Repatha and Praluent target the same pathway. Their use has remained limited partly because of higher costs, insurance barriers and the need for regular injections. As the first approved oral PCSK9 inhibitor, Lipfendra could make this form of treatment more convenient for eligible patients.

The approved dose is 20 mg once daily. The tablet should be taken in the morning on an empty stomach with water, black coffee or plain tea, and patients should wait at least 30 minutes before eating or drinking anything else.

Lipfendra price, availability and side effects

Merck has set a US list price of $315 for a 30-day supply, before insurance coverage, rebates or patient-assistance programmes. The company said Lipfendra is expected to become available within weeks of the approval.

That price is below the roughly $500 to $600 monthly list cost commonly associated with injectable PCSK9 medicines. The amount an individual pays will depend on insurance, pharmacy benefits, discounts and eligibility for financial assistance.

Coverage decisions will therefore play an important role in determining patient access. Wider Medicare reimbursement concerns and possible benefit cuts show how insurer payment changes can affect healthcare choices, while UnitedHealth’s Medicare-related earnings pressure reflects wider financial challenges across the US healthcare system.

Lipfendra was generally well tolerated in clinical trials. Diarrhoea and dizziness were among the more frequently reported side effects, while serious adverse events and treatment discontinuations occurred at rates broadly similar to those seen with placebo.

Does Lipfendra replace statins or prevent heart attacks?

Lipfendra is not intended to replace statins for most patients. Doctors may prescribe it alongside statins or other cholesterol-lowering medicines when further LDL reduction is needed. The most appropriate option will depend on cholesterol levels, cardiovascular risk, medical history and tolerance of existing treatments.

The medicine has demonstrated substantial LDL reduction, but it has not yet been proven to reduce heart attacks, strokes or cardiovascular deaths. A large cardiovascular-outcomes trial involving more than 14,000 participants is continuing, with results expected around 2029.

Merck’s official Lipfendra approval announcement provides further information about the approved use, clinical trials and safety findings.

Lipfendra is available by prescription only and is intended for adults who need additional LDL reduction alongside diet and other cholesterol-lowering therapies, as determined by their healthcare provider.

Lipfendra represents an important new option for cholesterol treatment, but it remains only one part of long-term cardiovascular care. Medication works best alongside a heart-healthy diet, regular physical activity, management of blood pressure and diabetes, and routine medical follow-up.